Osimertinib also improves overall survival in EGFR-mutated NSCLC

被引：0
|
作者：
Lichert, Frank
机构：
来源：
PNEUMOLOGIE | 2024年 / 78卷 / 03期
关键词：
D O I：
10.1055/a-2196-8365
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Innerhalb der Studie ADAURA hatte eine adjuvante Osimertinib-Therapie bei Patienten mit nicht kleinzelligem Lungenkarzinom (NSCLC) der Stadien IB-IIIA und EGFR-Mutation gegenuber Placebo ein signifikant langeres krankheitsfreies uberleben zu Folge. Nun wurden die Ergebnisse einer finalen Analyse zum Gesamtuberleben vorgestellt.
引用
收藏
页码：143 / 143
页数：1
相关论文
共 50 条
  • [31] Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC
    Zheng, Mei-Mei
    Li, Yang-Si
    Tu, Hai-Yan
    Jiang, Ben-Yuan
    Yang, Jin-Ji
    Zhou, Qing
    Xu, Chong-Rui
    Yang, Xiao-Rong
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : 250 - 258
  • [32] RELAY: final overall survival with erlotinib plus ramucirumab or placebo in untreated, EGFR-mutated metastatic NSCLC (mNSCLC)
    Nakagawa, K.
    Garon, E. B.
    Nishio, M.
    Seto, T.
    Nishio, K.
    Kasahara, K.
    Nishino, K.
    Satouchi, M.
    Yoh, K.
    Hayashi, H.
    Enatsu, S.
    Frimodt-Moller, B.
    Matsui, T.
    Varughese, S. C.
    Visseren-Grul, C.
    Reck, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1313 - S1313
  • [33] Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
    Merkhofer, Cristina M.
    Baik, Christina S.
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
  • [34] A prospective observational multicenter study on osimertinib resistance using ctDNA analysis in EGFR-mutated NSCLC
    Osuga, Mitsuo
    Tamiya, Akihiro
    Harada, Daijiro
    Mizumori, Yasuyuki
    Isa, Shunichi
    Taniguchi, Yoshihiko
    Nakamura, Keiichi
    Shinohara, Tsutomu
    Yanai, Hidetoshi
    Nakatomi, Katsumi
    Oki, Masahide
    Mori, Masahide
    Kuwako, Tomohito
    Yamazaki, Koji
    Ando, Masahiko
    Koh, Yasuhiro
    CANCER SCIENCE, 2025, 116 : 330 - 330
  • [35] Neoadjuvant Osimertinib with/without Chemotherapy versus Chemotherapy in Patients with EGFR-mutated resectable NSCLC: NeoADAURA
    Griesinger, F.
    Tsuboi, M.
    Weder, W.
    Escriu, C.
    Blakely, C.
    He, J.
    Dacic, S.
    Yatabe, Y.
    Zeng, L.
    Walding, A.
    Chaft, J.
    PNEUMOLOGIE, 2021, 75 : S6 - S7
  • [36] Liquid Biopsy and PET Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC
    Leonetti, A.
    Bola, S.
    Minari, R.
    Scarlattei, M.
    Buti, S.
    Bordi, P.
    Baldari, G.
    Gnetti, L.
    Sammartano, A.
    Migliari, S.
    Cosenza, A.
    Ferri, L.
    Bonatti, F.
    Mastrodomenico, L.
    Ruffini, L.
    Tiseo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S610 - S610
  • [37] EGFR-mutated NSCLC: A roadmap to treatment sequences
    Girard, Nicolas
    MED, 2024, 5 (09): : 1044 - 1047
  • [38] Resistance landscape to almonertinib in EGFR-mutated NSCLC
    Tian, M.
    Lu, Z.
    Chen, S.
    Lu, G.
    Bu, F.
    Deng, W.
    Ding, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1017 - S1017
  • [39] Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis
    Fan, Y.
    Wu, H.
    Chen, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S652 - S652
  • [40] Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
    Brouns, Anita J. W. M.
    van Veelen, Ard
    Veerman, G. D. Marijn
    Steendam, Christi
    Dursun, Safiye
    van der Leest, Cor
    Croes, Sander
    Dingemans, Anne-Marie C.
    Hendriks, Lizza E. L.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (05):
12345